This is a randomized phase II trial evaluating the efficacy of a nivolumab monotherapy lead in "window" or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers.

    Lead Trial Coordinator
    Holly Shaw

    Trial Coordinator
    Meredith Kissel

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990

    This email address is being protected from spambots. You need JavaScript enabled to view it.


    Targeted Accrual

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Phone: +41 31 511 94 00

    Member Login